<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管基本问题</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed=1Vuepj4z_tesaaxkwjxbogotaabxd6u-nvu8003krcppqpqpqpqpq8ylqc-＆ut_source = 2.18.024.post＆v = 2.18.0124.post9 708114047＆ff = 20250205072028＆utm_medium = rss＆utm_content = 1VUE PJ4Z_TESAAXKWJXBOGOTAABXD6U -NVU8003KRCPQ8LYLQC-<description>心血管田径：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;ff=20250205072028&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link><docs> http://www.rsboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate>星期三，2025年2月5日12:20:31 +0000</lastbuilddate><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title>逐步临时和系统的双层策略，用于治疗真正的左主冠状动脉分叉病变</title><link/>https://pubmed.ncbi.nlm.nih.gov/39907022/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250205072028&amp;v=2.18.0.post9+e462414<description>结论：在左手分叉冠状动脉疾病的欧洲人群中，需要在3年的逐步临时双层策略之间进行重大不良diofastival事件。对于非复杂性左主叉冠冠状动脉国际。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。2025年2月5日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：与系统的双固定方法相比，对真实左主分叉病变的最佳冠状动脉施加技术旨在评估逐步临时策略的临床结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：EBC Main是一个随机，研究者发射的，开放标签的，多中心的，平行组试验，在35个pean国家中进行了467个参与者的冠状动脉干预，以随机地与逐步的临时策略（N = 230）或前期双期方法（n = 237）。所有心肌梗死。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在3年中，主要终点是230<i>个</i>逐步临时的（23.5％）和237个（29.5％）O，0.75 [95％CI，0.53-1.07]；全因死亡率的显着差异（10.0％对13.1 <i>％</i> ）。 <i>）</i> <i>。</i> = 0.005），具有较小的血管（直径&lt;3.25毫米）和较短的病变（长度&lt;10 mm），有利于临时方法。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在左手分叉冠状动脉疾病的欧洲人群中，需要在3年的逐步临时双层策略之间进行重大不良diofastival事件。对于非复杂性左主叉冠冠状动脉国际。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：URL：https：//www.clinicaltrials.gov;</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071153>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39907022/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39907022</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39907022</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Sandeep Arunothayaraj</dc:creator><dc:creator> Mohaned Egred</dc:creator><dc:creator> Adrian P Banning</dc:creator><dc:creator>菲利普·布鲁内尔（Philippe Brunel）</dc:creator><dc:creator> Miroslaw Ferenc</dc:creator><dc:creator>托马斯·霍瓦斯（Thomas Hovasse）</dc:creator><dc:creator> Adrian Wlodarczak</dc:creator><dc:creator>曼努埃尔·潘（Manuel Pan）</dc:creator><dc:creator>托马斯·施密茨（Thomas Schmitz）</dc:creator><dc:creator>马克·西尔维斯特里（Marc Silvestri）</dc:creator><dc:creator>安德烈·埃格利斯（Andreis Erglis）</dc:creator><dc:creator> Evgeny Kretov</dc:creator><dc:creator> Jens Flensted Lassen</dc:creator><dc:creator> Alaide Chieffo</dc:creator><dc:creator> ThierryLefèvre</dc:creator><dc:creator> Francesco Burzotta</dc:creator><dc:creator>詹姆斯·科克本</dc:creator><dc:creator>奥利维尔·达雷蒙特（Olivier Darremont）</dc:creator><dc:creator> Goran Stankovic</dc:creator><dc:creator>玛丽·克劳德·莫里斯（Marie-Claude Morice）</dc:creator><dc:creator>伊夫·卢瓦德（Yves Louvard）</dc:creator><dc:creator>大卫·希尔迪克·史密斯（David Hildick-Smith）</dc:creator><dc:date> 2025-02-05</dc:date><dc:source>循环</dc:source><dc:title>逐步临时和系统的双层策略，用于治疗真正的左主冠状动脉分叉病变</dc:title><dc:identifier>PMID：39907022</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.071153</dc:identifier></item><item><title> CD4 &lt;Sup>;+&lt;/sup>; T CD4 D在内皮NADPH氧化酶1中增加</title><link/>https://pubmed.ncbi.nlm.nih.gov/39907014/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250205072028&amp;v=2.18.0.post9+e462414<description>结论：我们首先证明了表达Hival蛋白的CD4^（+）T细胞通过血管NOX1中的IL-1α-Medias ES诱导高血压，这会损害男性和女性的其他功能。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。2025年2月5日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：Althooth组合抗逆转录病毒疗法增加了HIV的生活，这导致了高血压患病率的标记，其原因是CD4 <sup>+</sup> T淋巴细胞中的HIV中的艾滋病毒。高血压和内皮依赖性受损仍未定义。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：表达病毒蛋白的CD4 <sup>+</sup> T细胞使用TE G26小鼠模型有助于内皮功能障碍和高血压。 BMT），CD4 <sup>+</sup> T细胞的过继转移和从HIV患者中丢弃的主动脉标本。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们报道了接收BMT（TG26→WT）的TG26小鼠或TG26小鼠的CD4 <sup>+</sup> T细胞表现出<sup>暗示</sup>性的ENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENDENTAIL，对话，从WT小鼠中进行BMT。 T细胞耗尽的TG26小鼠的内皮内皮FUOD压力揭示了TG26小鼠，TG26 26 CD4 <sup>+</sup> T细胞始终表现出高介粒细胞介素1α（IL-1α）水平，而其他细胞因子不显着增加，WT小鼠降低了TG26小鼠的IL-1α TG26小鼠的<sup>水平</sup><sup>。</sup> 1α中和抗体。 TG26 BMT i的内皮依赖性弛豫和高血压。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们首先证明CD4 <sup>+</sup> T细胞通过IL-1α介导的增加的血管NOX1表达HIV病毒蛋白诱导高血压，这会损害男性和女性的其他功能。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070538>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39907014/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39907014</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39907014</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator>泰勒·克雷斯（Taylor C Kress）</dc:creator><dc:creator> Candee T Barris</dc:creator><dc:creator> laszlo kovacs</dc:creator><dc:creator> Beryl N Khakina</dc:creator><dc:creator> Coleton R Jordan</dc:creator><dc:creator> Thiago Bruder-Nascimento</dc:creator><dc:creator> David W Stepp</dc:creator><dc:creator>罗杰·麦克阿瑟（Rodger MacArthur）</dc:creator><dc:creator> Vijay S Patel</dc:creator><dc:creator> Jie Chen</dc:creator><dc:creator> Rafal Pacholczyk</dc:creator><dc:creator>西蒙妮·肯纳德（Simone Kennard）</dc:creator><dc:creator> Eric J Belin de Chantemle</dc:creator><dc:date> 2025-02-05</dc:date><dc:source>循环</dc:source><dc:title>CD4 &lt;Sup>;+&lt;/sup>; T CD4 D在内皮NADPH氧化酶1中增加</dc:title><dc:identifier>PMID：39907014</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.070538</dc:identifier></item><item><title> Irbesartan在Celiprololol治疗的Pascular Ehlers-Danlos综合征中的功效</title><link/>https://pubmed.ncbi.nlm.nih.gov/39906986/？ 708114047＆ff = 20250205072028＆v = 2.18.0.post9+E462414<description>结论：与安慰剂相比，Irbesartan降低了在背景celiprololol治疗的血管LERS-DANLOS综合征患者中严重症状动脉动脉事件的风险。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。2025年2月5日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：血管ehlers-danlos综合征是一种罕见的遗传疾病，其特征是III胶原蛋白，而动脉疾病和死亡率迄今为止。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：一项多层次，安慰剂对照试验在稳定的背景celiprolol疗法上，血管紧张素II BESARTAN在具有稳定背景的成年人中的疗效和安全性复合主要结局定义为任何致命或非致命的人工事件，或者使用系统的从头到眼基督计算机层析成像血管造影检测到的任何新的或恶化的动脉病变，或在不同的时间点，使用不同的时间点，使用的时间点，分析。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：29名参与者（62％的女性； 40.3±11.3岁）随机分配给Irbesartan，28岁（64％的女性； 40.7±11.0岁）随机分配给安慰剂。 29例接受IRBESARTAN的患者（27.6％）接受安慰剂的28例患者中的15例（53.6％）接受安慰剂<i>（</i>危险比，0.42 [95％CI，0.17，0.99]，他患有症状性或非症状的毒性毒性事件的风险比安慰剂较低（ 95％CI，0.68]; <i>p</i> = 0.002） <i>。</i> 4例患者的下降。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与安慰剂相比，Irbesartan降低了在背景celiprololol治疗的血管LERS-DANLOS综合征患者中严重症状动脉动脉事件的风险。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：URL：https：//www.clinicaltrials.gov;</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072849>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39906986/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39906986</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39906986</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Xavier Jeunemaitre</dc:creator><dc:creator> Elie Mousseaux</dc:creator><dc:creator>迈克尔·弗兰克</dc:creator><dc:creator>萨尔玛·阿德姆</dc:creator><dc:creator>Francesca Pitocco</dc:creator><dc:creator>克拉丽丝·比隆</dc:creator><dc:creator>Molka Ben Yakhlef</dc:creator><dc:creator>穆罕默德·埃尔·哈希米（Mohamed El Hachmi）</dc:creator><dc:creator> Alessandra Bura-Rivière</dc:creator><dc:creator> François-XavierLapébie</dc:creator><dc:creator>克莱尔·勒（Claire le Hello）</dc:creator><dc:creator>达米安·莱内尔（Damien Laneelle）</dc:creator><dc:creator>克里斯托夫·塞敦库（Christophe Seinturier）</dc:creator><dc:creator>克劳斯·迪特里奇（Klaus Dieterich）</dc:creator><dc:creator>马克·兰伯特</dc:creator><dc:creator>Sophie Dupuis-Girlod</dc:creator><dc:creator>斯蒂芬·齐里（Stephane Zuily）</dc:creator><dc:creator>劳伦斯·巴尔托利耶尔</dc:creator><dc:creator>卡琳·布隆</dc:creator><dc:creator>皮尔里克·亨尼顿（Pierrick Henneton）</dc:creator><dc:creator> Estelle Lu</dc:creator><dc:creator>尼古拉斯·丹纳里（NicolasDenarié）</dc:creator><dc:creator>皮埃尔·布托伊里（Pierre Boutouyrie）</dc:creator><dc:creator> Tristan Mirault</dc:creator><dc:creator>吉尔斯·查尔利尔（Gilles Chatellier）</dc:creator><dc:creator>米歇尔·阿齐兹（Michel Azizi）</dc:creator><dc:date> 2025-02-05</dc:date><dc:source>循环</dc:source><dc:title>Irbesartan在Celiprololol治疗的Pascular Ehlers-Danlos综合征中的功效</dc:title><dc:identifier>PMID：39906986</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.072849</dc:identifier></item><item><title>临床效用和预测心血管疾病的多基因风险评分的实施</title><link/>https://pubmed.ncbi.nlm.nih.gov/39906985/？ 708114047＆ff = 20250205072028＆v = 2.18.0.post9+E462414<description>全基因组关联研究与心血管疾病相关的数百种遗传变异（CVD）可以在单个度量标准中捕获这些信息，并有望在CVD风险中使用。个人是裸露的生活。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 2月5日：Ehae649。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">全基因组关联研究与心血管疾病相关的数百种遗传变异（CVD）可以在单个度量标准中捕获这些信息，并有望在CVD风险中使用。个人在常规的临床实践中使用了暴露的生活。迄今为止，出于疾病的目的，他们在C. VD中的作用进行了预测。 l社区可以将未来的公关过渡到常规的临床护理。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1093/eurheartj/ehae649>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39906985/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39906985</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39906985</guid><pubDate> Wed, 05 Feb 2025 06:00:00 -0500</pubDate><dc:creator>赫里伯特·尚克特（Heribert Schunkert）</dc:creator><dc:creator> Emanuele di Angelantonio</dc:creator><dc:creator>迈克尔·乌诺耶（Michael Inouye）</dc:creator><dc:creator> Riyaz的Patel</dc:creator><dc:creator> Samuli Ripatti</dc:creator><dc:creator>伊丽莎白·加宽</dc:creator><dc:creator>萨斯基亚C桑德森</dc:creator><dc:creator>胡安·帕勃罗·卡斯基（Juan Pablo Kaski）</dc:creator><dc:creator>约翰·W·梅切沃伊（John W McEvoy）</dc:creator><dc:creator> Panos Vardas</dc:creator><dc:creator>安吉拉·伍德</dc:creator><dc:creator>Victor Aboyans</dc:creator><dc:creator> Vassilios S Vassiliou</dc:creator><dc:creator>弗兰克·LJ Visseren</dc:creator><dc:creator>路易斯·洛佩斯</dc:creator><dc:creator>佩里·埃利奥特（Perry Eliott）</dc:creator><dc:creator> Maryam Kavousi</dc:creator><dc:date> 2025-02-05</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>临床效用和预测心血管疾病的多基因风险评分的实施</dc:title><dc:identifier>PMID：39906985</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehae649</dc:identifier></item><item><title>用于诊断Takotsubo综合征的心脏生物标志物：保持简单吗？</title><link/> https://pubmed.ncbi.nlm.nih.gov/39902777/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250205072028&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 2月4日：Ehae765：10.1093/EurheartJ/Ehae765。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1093/eurheartj/ehae765>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39902777/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39902777</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39902777</guid><pubDate> Tue, 04 Feb 2025 06:00:00 -0500</pubDate><dc:creator>奥利维尔·加赫（Olivier Gach）</dc:creator><dc:creator>查尔斯·皮雷特（Charles Pirlet）</dc:creator><dc:date> 2025-02-04</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>用于诊断Takotsubo综合征的心脏生物标志物：保持简单吗？</dc:title><dc:identifier> PMID：39902777</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehae765</dc:identifier></item><item><title>预测性心词：将单细胞多构想转化为个性化医学工具</title><link/>https://pubmed.ncbi.nlm.nih.gov/39900732/？ 08114047＆ff = 20250205072028＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1038/s41569-025-01132-3>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39900732/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39900732</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39900732</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Kami Pekayvaz</dc:creator><dc:creator>马蒂亚斯·海尼格（Matthias Heinig）</dc:creator><dc:creator> Konstantin Stark</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>自然评论</dc:source><dc:title>预测性心词：将单细胞多构想转化为个性化医学工具</dc:title><dc:identifier>PMID：39900732</dc:identifier><dc:identifier> doi：10.1038/s41569-025-01132-3</dc:identifier></item><item><title>临床证据的胜利：国际肺栓塞治疗国际策略的首次面对面试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/39899637/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250205072028&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。2025年2月4日；</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072972>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39899637/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39899637</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39899637</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Sunil V Rao</dc:creator><dc:creator> J Antonio T Gutierrez</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>循环</dc:source><dc:title>临床证据的胜利：国际肺栓塞治疗国际策略的首次面对面试验</dc:title><dc:identifier>PMID：39899637</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.072972</dc:identifier></item><item><title>如果我们相信我们对精密医学的看法，请测量载脂蛋白B</title><link/> https://pubmed.ncbi.nlm.nih.gov/39899636/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250205072028&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。2025年2月4日； 157-259。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067559>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39899636/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39899636</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39899636</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator>安娜·沃尔斯卡（Anna Wolska）</dc:creator><dc:creator>唐纳德·M·劳埃德·琼斯（Donald M Lloyd-Jones）</dc:creator><dc:creator> Alan T Remaley</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>循环</dc:source><dc:title>如果我们相信我们对精密医学的看法，请测量载脂蛋白B</dc:title><dc:identifier> PMID：39899636</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.123.067559</dc:identifier></item><item><title> Wang和Peng Legarding文章的信：“病毒引起的Accentory遇险综合征通过心脏中引起的Ory反应引起心肌病”</title><link/> https://pubmed.ncbi.nlm.nih.gov/39899635/？ 708114047＆ff = 20250205072028＆v = 2.18.0.post9+E462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。2025年2月4日；</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069798>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39899635/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39899635</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39899635</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator>徐王</dc:creator><dc:creator>小彭</dc:creator><dc:date>2025-02-03</dc:date><dc:source>循环</dc:source><dc:title>Wang和Peng Legarding文章的信：“病毒引起的Accentory遇险综合征通过心脏中引起的Ory反应引起心肌病”</dc:title><dc:identifier> PMID：39899635</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.069798</dc:identifier></item><item><title>测量临床试验中的抑制性</title><link/>https://pubmed.ncbi.nlm.nih.gov/39899634/？ 708114047＆ff = 20250205072028＆v = 2.18.0.post9+E462414<description>随机群体中的代表性仍然是一个关键的问题，对临床研究的审判结果，E风险和收益的外部阀门，E的风险和好处。属于临床试验，可以进行量化，从而使利益相关者可以添加经验。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。20252月4日；</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">随机群体中的代表性仍然是一个关键的问题，对临床研究的临床研究中的审判结果，E风险和收益的外部阀门，E的风险和收益不足。临床试验，可以量化i剂，公平性，包容性和归属范围。 S具有优势，在某些情况下可能适合SS，包括监管机构，期刊编辑，临床试验研究人员，并使用量子量但是，以这种方式使用代表性的定量衡量标准可能会带来意外的后果，但忽略了细微的变化，但没有单一的方法来衡量抑制性NESS，可以提供多种多样的解决方案在所有随机临床试验中，都具有有用的观点来衡量衡量进度的临床试验的多样性。但是，对于代表性的更细微的观点，占优势的比率是相关性亚组中的入学率组合，以及对入学率的患者人口统计的完整报告。</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070299>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39899634/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39899634</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39899634</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator>艾伦·萨尼（Allen Sanyi）</dc:creator><dc:creator> Samuel Byiringiro</dc:creator><dc:creator> Sanaz Dabiri</dc:creator><dc:creator> Mireille Jacobson</dc:creator><dc:creator>阿曼达·博伊德（Amanda Boyd）</dc:creator><dc:creator> Modele Ogunniyi</dc:creator><dc:creator>阿兰娜（Alanna）莫里斯（Morris）</dc:creator><dc:creator>瑞秋·科恩（Rachel Kohn）</dc:creator><dc:creator> Neal W Dickert</dc:creator><dc:creator> Meghan B Lane-Parl</dc:creator><dc:creator> Eldrin F Lewis</dc:creator><dc:creator> Scott D Halpern</dc:creator><dc:creator>亚历山大·坎纳罗夫（Alexander C Fanaroff）</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>循环</dc:source><dc:title>测量临床试验中的抑制性</dc:title><dc:identifier>PMID：39899634</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.070299</dc:identifier></item><item><title>出血性中风后心房颤动的风险：倾向得分匹配的国家</title><link/>https://pubmed.ncbi.nlm.nih.gov/39899633/?utm_source=chrome&amp;utm_medium = rsss＆utm_campaign = pubmed-2＆utm_campaign = 708114047＆ff = 20250205072028＆v = 2.18.0.post9+E462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。2025年2月4日；</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070662>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39899633/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39899633</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39899633</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Jihun Kang</dc:creator><dc:creator> Jung Eun Yoo</dc:creator><dc:creator> Byeoung-Jun Jeon</dc:creator><dc:creator>演唱il im</dc:creator><dc:creator> Bongseong Kim</dc:creator><dc:creator>赢得了Hyuk Chang</dc:creator><dc:creator> Kyungdo Han</dc:creator><dc:creator>邓·旺·辛（Dong Wook Shin）</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>循环</dc:source><dc:title>出血性中风后心房颤动的风险：倾向得分匹配的国家</dc:title><dc:identifier>PMID：39899633</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.070662</dc:identifier></item><item><title>遗传预测的IL-18抑制和心血管事件的风险：孟德尔随机研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/39899632/？ 708114047＆ff = 20250205072028＆v = 2.18.0.post9+E462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072238>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39899632/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39899632</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39899632</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator>斯蒂芬·奥·布伦南（Stephen O Brennan）</dc:creator><dc:creator>彼得·J·凯利</dc:creator><dc:creator>莎拉·戈里（Sarah Gorey）</dc:creator><dc:creator> PádraigSynnott</dc:creator><dc:creator> Dipender Gill</dc:creator><dc:creator>马丁·二十邦</dc:creator><dc:creator>Marios K Georgakis</dc:creator><dc:creator>玛丽·乔·迪布（Marie-Joe Dib）</dc:creator><dc:creator> Eloi Gagnon</dc:creator><dc:creator> Niall Mahon</dc:creator><dc:creator>加文·布雷克（Gavin J Blake）</dc:creator><dc:creator>克里斯蒂娜·杰恩（Christina Jern）</dc:creator><dc:creator>休·马克斯（Hugh S Markus）</dc:creator><dc:creator>威廉·怀特利（William Whiteley）</dc:creator><dc:creator>约翰·J·麦凯布（John J McCabe）</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>循环</dc:source><dc:title>遗传预测的IL-18抑制和心血管事件的风险：孟德尔随机研究</dc:title><dc:identifier>PMID：39899632</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.072238</dc:identifier></item><item><title> Grune和Nahrendorf对有关引起心脏炎症反应的文章的信的反应”</title><link/> https://pubmed.ncbi.nlm.nih.gov/39899631/？ 708114047＆ff = 20250205072028＆v = 2.18.0.post9+E462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。2025年2月4日；</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072688>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39899631/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39899631</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39899631</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Jana Grune</dc:creator><dc:creator> Matthias Nahrendorf</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>循环</dc:source><dc:title>Grune和Nahrendorf对有关引起心脏炎症反应的文章的信的反应”</dc:title><dc:identifier> PMID：39899631</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.072688</dc:identifier></item><item><title>系统评价，荟萃分析和人群研究，以确定扩张性心肌病的生物性比例</title><link/>https://pubmed.ncbi.nlm.nih.gov/39895490/？ 708114047＆ff = 20250205072028＆v = 2.18.0.post9+E462414<description>结论：这项研究表明，在男性患者中，DCM是普遍存在的两倍。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。2025年2月3日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：在女性患者中，假肌病（DCM）似乎被诊断为女性患者系统的综述，荟萃分析和人口研究是与DCM的性别比，按遗传状态分层，并通过诊断偏见评估了窃窃私语的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：文献确定了具有可见性比率的DCM患者队列。 ，将单个选择的DCM基因（ <i>TTN</i>和<i>LMNA</i> ）和难以捉摸的DCM与使用生物库成像的性别的诊断剂进行了比较。 - 首先和基因型优先确定的性别比。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：总共99项研究，37 525总体DCM队列的女性比例为0.30（95％CI，0.28-0.32）与男性：女性比率（M：F）为2.38：1。具有ITIFIED DCM变体的患者（95％CI，0.26-0.36]; M：F 2.22：1; <i>P</i> = 0.56）。 ：1 <i>;</i> <i>p</i> = <i>0.81</i> <i>）</i> 。 CI，0.27-0.44]； M：F 1.84：1; <i>p</i> = 0.41）。 <i>p</i> = 0.19）银行（n = 47 549），由国际疾病分类定义的DCM，第10修订，编码为4.5：1 m-最新诊断方法分别将其更改为1.7：1：1和2.3：1。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项研究表明，在男性患者中，DCM是普遍存在的两倍。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：URL：https：//www.crd.york.ac.uk/prospero;</p><p style="color: lightgray"> PMID <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070872>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39895490/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39895490</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39895490</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator>娜塔莉·伯根（Natalie Bergan）</dc:creator><dc:creator> Ishika Prachee</dc:creator><dc:creator>拉拉·柯伦（Lara Curran）</dc:creator><dc:creator>凯瑟琳·麦格克（Kathryn A McGurk）</dc:creator><dc:creator> Chang Lu</dc:creator><dc:creator>安东尼奥·德·马瓦（Antonio de Marvao）</dc:creator><dc:creator> Wenjia Bai</dc:creator><dc:creator> Brian P Halliday</dc:creator><dc:creator>约翰·格雷格森（John Gregson）</dc:creator><dc:creator> Declan P O&#39;Regan</dc:creator><dc:creator>詹姆斯·韦尔</dc:creator><dc:creator>Upasana Tayal</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>循环</dc:source><dc:title>系统评价，荟萃分析和人群研究，以确定扩张性心肌病的生物性比例</dc:title><dc:identifier>PMID：39895490</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.070872</dc:identifier></item><item><title>专注于光谱的极端：没有阻塞性冠状动脉改变和缺血性心肌病的心肌梗死</title><link/>https://pubmed.ncbi.nlm.nih.gov/39895466/？ 708114047＆ff = 20250205072028＆v = 2.18.0.post9+E462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 2月3日； 46（5）：399-403。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1093/eurheartj/ehae891>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39895466/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39895466</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39895466</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Filippo Crea</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>专注于光谱的极端：没有阻塞性冠状动脉改变和缺血性心肌病的心肌梗死</dc:title><dc:identifier>PMID：39895466</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehae891</dc:identifier></item><item><title>赋予专业权力：ACC对尖端临床指导的承诺</title><link/>https://pubmed.ncbi.nlm.nih.gov/39895434/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250205072028&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J AM Coll Cardiol。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1016/j.jacc.2025.01.006>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39895434/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39895434</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39895434</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Cathleen Biga</dc:creator><dc:creator>安娜·巴拉克</dc:creator><dc:creator>妮可·巴夫（Nicole Bhave）</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>美国心脏病学院杂志</dc:source><dc:title>赋予专业权力：ACC对尖端临床指导的承诺</dc:title><dc:identifier>PMID：39895434</dc:identifier><dc:identifier> doi：10.1016/j.jacc.2025.01.006</dc:identifier></item><item><title>保加利亚心脏病学会：50年</title><link/>https://pubmed.ncbi.nlm.nih.gov/39895398/？ 708114047＆ff = 20250205072028＆v = 2.18.0.post9+E462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 2月3日：Ehae916。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1093/eurheartj/ehae916>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39895398/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39895398</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39895398</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Vassil Traykov</dc:creator><dc:creator> Kiril Karamfiloffff</dc:creator><dc:creator> Assen Goudev</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>保加利亚心脏病学会：50年</dc:title><dc:identifier>PMID：39895398</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehae916</dc:identifier></item><item><title>心脏病学领导者：朱莉·德·支持者</title><link/>https://pubmed.ncbi.nlm.nih.gov/39895379/？ 708114047＆ff = 20250205072028＆v = 2.18.0.post9+E462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 2月3日：Ehae884。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1093/eurheartj/ehae884>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/39895379/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39895379</a> |</p></div> ]>;]]</content:encoded><guid ispermalink="false"> PubMed：39895379</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator>朱迪思·奥兹坎（Judith Ozkan）</dc:creator><dc:date> 2025-02-03</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>心脏病学领导者：朱莉·德·支持者</dc:title><dc:identifier>PMID：39895379</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehae884</dc:identifier></item><item><title> Asymptomatic atrial fibrillation: the tasks ahead</title><link/> https://pubmed.ncbi.nlm.nih.gov/39895147/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250205072028&amp;v=2.18.0.post9+e462414<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 Feb 3:ehae835. doi: 10.1093/eurheartj/ehae835. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39895147/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39895147</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehae835>10.1093/eurheartj/ehae835</a></p></div> ]>;]]</content:encoded><guid ispermalink="false"> pubmed:39895147</guid><pubDate> Mon, 03 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Marc Lemoine</dc:creator><dc:creator> Laura Rottner</dc:creator><dc:creator> Paulus Kirchhof</dc:creator><dc:date> 2025-02-03</dc:date><dc:source> European heart journal</dc:source><dc:title> Asymptomatic atrial fibrillation: the tasks ahead</dc:title><dc:identifier> pmid:39895147</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehae835</dc:identifier></item><item><title> Hospitalization for cardiovascular disease in the year after delivery of twin pregnancies</title><link/> https://pubmed.ncbi.nlm.nih.gov/39894055/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250205072028&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: Compared with singletons without HDP, twin pregnancies, even in the absence of HDP, are associated with increased risks for CVD complications in the first year post-partum. These findings highlight the increased strain twin pregnancies place on the maternal cardiovascular system. These findings advocate the need for appropriate pre-conception counselling for those with cardiovascular risk factors undergoing infertility treatment, which increase the risks of multi-foetal gestation,... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 Feb 3:ehaf003. doi: 10.1093/eurheartj/ehaf003. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Increased cardiovascular demand in twin pregnancies, even those without hypertensive disease of pregnancy (HDP), may pose a greater risk for cardiovascular complications compared with singletons. In this study, the risk of cardiovascular disease (CVD)-related hospitalizations and mortality within the year following delivery in relation to HDP was compared between twin and singleton pregnancies. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Using the Nationwide Readmissions Database of US hospitals from 2010 to 2020, the rates of CVD readmission in four exposure groups (twin deliveries with and without HDP and singleton deliveries with and without HDP) were estimated. Cox proportional hazard regression models were used to determine associations with singletons without HDP as the reference. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：与没有HDP相比，双胞胎和单胎怀孕的CVD再入院率分别为1105.4和734.1。使用HDP [HR 8.21，95％置信区间（CI）7.48-9.01]，其次是具有HDP的单例（HR 5.89，95％CI 5.70-6.08），然后是没有HDP的双胞胎（HR 1.95，95％CI 1.75，2.17） 。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Compared with singletons without HDP, twin pregnancies, even in the absence of HDP, are associated with increased risks for CVD complications in the first year post-partum. These findings highlight the increased strain twin pregnancies place on the maternal cardiovascular system. These findings advocate the need for appropriate pre-conception counselling for those with cardiovascular risk factors undergoing infertility treatment, which increase the risks of multi-foetal gestation, and increased post-partum surveillance in twin pregnancies.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39894055/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39894055</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehaf003>10.1093/eurheartj/ehaf003</a></p></div> ]>;]]</content:encoded><guid ispermalink="false"> pubmed:39894055</guid><pubDate> Sun, 02 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Ruby Lin</dc:creator><dc:creator> Jessica C Fields</dc:creator><dc:creator> Rachel Lee</dc:creator><dc:creator> Emily B Rosenfeld</dc:creator><dc:creator> Emily E Daggett</dc:creator><dc:creator> Ruchira Sharma</dc:creator><dc:creator> Cande V Ananth</dc:creator><dc:date> 2025-02-02</dc:date><dc:source> European heart journal</dc:source><dc:title> Hospitalization for cardiovascular disease in the year after delivery of twin pregnancies</dc:title><dc:identifier> pmid:39894055</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehaf003</dc:identifier></item><item><title> Double double, future trouble? Opportunities for cardio-obstetric collaboration to reduce future cardiovascular events following twin pregnancies</title><link/> https://pubmed.ncbi.nlm.nih.gov/39894054/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250205072028&amp;v=2.18.0.post9+e462414<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 Feb 3:ehaf064. doi: 10.1093/eurheartj/ehaf064. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39894054/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250205072028&v=2.18.0.post9+e462414">39894054</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehaf064>10.1093/eurheartj/ehaf064</a></p></div> ]>;]]</content:encoded><guid ispermalink="false"> pubmed:39894054</guid><pubDate> Sun, 02 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Alexandria F Williams</dc:creator><dc:creator> Anne Marie Valente</dc:creator><dc:creator> Katherine E Economy</dc:creator><dc:date> 2025-02-02</dc:date><dc:source> European heart journal</dc:source><dc:title> Double double, future trouble? Opportunities for cardio-obstetric collaboration to reduce future cardiovascular events following twin pregnancies</dc:title><dc:identifier> pmid:39894054</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehaf064</dc:identifier></item></channel></rss>